{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:41:54Z","timestamp":1790678514615,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.schres.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T02:23:25Z","timestamp":1603333405000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Longitudinal study of inflammatory markers and psychopathology in schizophrenia"],"prefix":"10.1016","volume":"224","author":[{"given":"Tami","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-4515","authenticated-orcid":false,"given":"Brian J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.schres.2020.10.003_bb0005","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00213-015-4044-5","article-title":"Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?","volume":"233","author":"Baumeister","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2020.10.003_bb0010","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2007.12.007","article-title":"Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans","volume":"63","author":"Brydon","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"44","key":"10.1016\/j.schres.2020.10.003_bb0015","doi-asserted-by":"crossref","first-page":"15369","DOI":"10.1523\/JNEUROSCI.2521-12.2012","article-title":"Leptin regulates dopamine responses to sustained stress in humans","volume":"32","author":"Burghardt","year":"2012","journal-title":"J. Neurosci."},{"issue":"14","key":"10.1016\/j.schres.2020.10.003_bb0020","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"Cakici","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2020.10.003_bb0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.psychres.2018.07.041","article-title":"The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia","volume":"268","author":"Dahan","year":"2018","journal-title":"Psychiatry Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.10.003_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","article-title":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","volume":"154","author":"de Witte","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.10.003_bb0035","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1523\/JNEUROSCI.3567-08.2009","article-title":"Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation","volume":"29","author":"D'Mello","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2020.10.003_bb0040","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.biopsych.2010.06.010","article-title":"Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward","volume":"68","author":"Eisenberger","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.10.003_bb3030","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.biopsych.2007.05.026","article-title":"Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression","volume":"62","author":"Felger","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.10.003_bb0050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1471-4159.2009.06325.x","article-title":"Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications","volume":"111","author":"Gaspar","year":"2009","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.schres.2020.10.003_bb0055","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/acps.13019","article-title":"Association between leptin levels and severity of suicidal behaviour in schizophrenia spectrum disorders","volume":"139","author":"Gohar","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2020.10.003_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2018.02.048","article-title":"TNF-alpha and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia","volume":"199","author":"Goldsmith","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.10.003_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbi.2014.12.004","article-title":"Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: preliminary findings","volume":"46","author":"Haroon","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.10.003_bb0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/NDT.S218483","article-title":"The role of cytokines in predicting the efficacy of acute stage treatment in patients with schizophrenia","volume":"16","author":"He","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2020.10.003_bb0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.schres.2019.04.021","article-title":"Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"209","author":"Kelly","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.10.003_bb0080","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fpsyt.2018.00753","article-title":"Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics","volume":"9","author":"Kroken","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.schres.2020.10.003_bb0085","first-page":"R652","article-title":"Central administration of rat IL-6 induces HPA activation and fever but not sickness behavioral in rats","volume":"276","author":"Lenczowski","year":"1999","journal-title":"Am. J. Phys."},{"issue":"10","key":"10.1016\/j.schres.2020.10.003_bb0090","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.euroneuro.2015.06.008","article-title":"Biomarkers of treatment outcome in schizophrenia: defining a benchmark for clinical significance","volume":"25","author":"Levine","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2020.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2020.10.003_bb0100","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","article-title":"CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature","volume":"21","author":"Louveau","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2020.10.003_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-003-1750-1","article-title":"Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia","volume":"174","author":"Martin","year":"2004","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.schres.2020.10.003_bb0110","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.schres.2020.10.003_bb2020","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1093\/schbul\/sbz021.253","article-title":"Meta-analysis of cytokine levels and psychopathology in schizophrenia","volume":"45","author":"Miller","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2020.10.003_bb0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/npp.2016.211","article-title":"Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions","volume":"42","author":"Miller","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2020.10.003_bb0120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.schres.2020.10.003_bb0125","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.10.003_bb0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2012.03.010","article-title":"Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies","volume":"42","author":"Miller","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.10.003_bb0135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.10.003_bb0140","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fpsyt.2019.00892","article-title":"Cytokine alterations in schizophrenia: an updated review","volume":"10","author":"Momtazmanesh","year":"2019","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.10.003_bb0145","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","article-title":"Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis","volume":"41","author":"Mondelli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2020.10.003_bb0150","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"Muller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.10.003_bb0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.psyneuen.2014.08.017","article-title":"Serum leptin and its relationship with psychopathology in schizophrenia","volume":"50","author":"Nurjono","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2020.10.003_bb0160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbi.2009.04.005","article-title":"To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers","volume":"23","author":"O\u2019Connor","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.10.003_bb0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainres.2010.04.028","article-title":"Modulation of the mesolimbic dopamine system by leptin","volume":"1350","author":"Opland","year":"2010","journal-title":"Brain Res."},{"issue":"3 Suppl 2","key":"10.1016\/j.schres.2020.10.003_bb0170","first-page":"S26","article-title":"Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis","volume":"60","author":"Potvin","year":"2015","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.schres.2020.10.003_bb0175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbi.2007.05.005","article-title":"Brain-immune communication pathways","volume":"21","author":"Quan","year":"2007","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2020.10.003_bb0180","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.biopsych.2010.04.019","article-title":"Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol","volume":"68","author":"Raison","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.10.003_bb0185","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neuron.2012.10.021","article-title":"The mysterious motivational functions of mesolimbic dopamine","volume":"76","author":"Salamone","year":"2012","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.schres.2020.10.003_bb0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/schbul\/sbt105","article-title":"Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways","volume":"40","author":"Schwarz","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.10.003_bb1010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.schres.2020.10.003_bb0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00213-013-3382-4","article-title":"Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia","volume":"231","author":"Song","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2020.10.003_bb0200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","article-title":"Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis","volume":"63","author":"Stubbs","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"1\u20132","key":"10.1016\/j.schres.2020.10.003_bb0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neures.2013.07.003","article-title":"Relationships between serum leptin level and severity of positive symptoms in schizophrenia","volume":"77","author":"Takayanagi","year":"2013","journal-title":"Neurosci. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.10.003_bb0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","article-title":"Antipsychotics\u2019 effects on blood levels of cytokines in schizophrenia: a meta-analysis","volume":"151","author":"Tourjman","year":"2013","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2020.10.003_bb0215","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/WNF.0b013e3181fa2a6f","article-title":"A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia","volume":"33","author":"Venkatasubramanian","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.schres.2020.10.003_bb0220","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3810\/pgm.2011.01.2252","article-title":"C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians","volume":"123","author":"Windgassen","year":"2011","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.schres.2020.10.003_bb0225","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.10.003_bb0230","doi-asserted-by":"crossref","first-page":"e100018","DOI":"10.1136\/gpsych-2018-100018","article-title":"Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia","volume":"31","author":"Xu","year":"2018","journal-title":"Gen. Psychiatr."},{"key":"10.1016\/j.schres.2020.10.003_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0006-8993(94)90006-X","article-title":"Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6","volume":"643","author":"Zalcman","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2020.10.003_bb0240","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0006-8993(99)02063-6","article-title":"Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats","volume":"847","author":"Zalcman","year":"1999","journal-title":"Brain Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420304904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420304904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:38:14Z","timestamp":1760297894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420304904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":50,"alternative-id":["S0920996420304904"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.10.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal study of inflammatory markers and psychopathology in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}